CA
VTYX

Continuum Advisory’s Ventyx Biosciences VTYX Stock Holding History

Continuum Advisory’s Portfolio VTYX Stock Details VTYX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$438 – 1946
2024
Q4 		$438 Hold
200
– – ﹤0.01% 1759
2024
Q3 		$394 Buy
+200
New +$460 ﹤0.01% 1829

Other funds holding VTYX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Continuum Advisory's VTYX Position: Q1 2025 in Review

Continuum Advisory sold out of Ventyx Biosciences (VTYX) in Q1 2025, closing a stake of 200 shares — an estimated $438 sold.

Continuum Advisory first reported a position in VTYX in Q3 2024 and held it in 2 quarters. The position peaked at $438 in Q4 2024. 116 funds tracked by Wall St. Rank hold VTYX as of Q1 2025.

  • Continuum Advisory reported no remaining Ventyx Biosciences position as of Q1 2025 after selling out during the quarter.
  • Continuum Advisory sold 200 Ventyx Biosciences shares in Q1 2025, an estimated $438.
  • Continuum Advisory first reported a position in Ventyx Biosciences in Q3 2024 and held it in 2 quarters.
  • Continuum Advisory's Ventyx Biosciences position peaked at $438 in Q4 2024.
  • 116 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q1 2025.

Based on Continuum Advisory's 13F filing for Q1 2025, filed 23 Apr 2025.